Becton Dickinson and Co (BDX) : Pathstone Family Office scooped up 10 additional shares in Becton Dickinson and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 2,621 shares of Becton Dickinson and Co which is valued at $454,796.Becton Dickinson and Co makes up approximately 0.48% of Pathstone Family Office’s portfolio.
Other Hedge Funds, Including , Btim Corp. reduced its stake in BDX by selling 1,685 shares or 0.36% in the most recent quarter. The Hedge Fund company now holds 463,159 shares of BDX which is valued at $80,367,350. Becton Dickinson and Co makes up approx 1.33% of Btim Corp.’s portfolio.Blair William Coil boosted its stake in BDX in the latest quarter, The investment management firm added 3,731 additional shares and now holds a total of 24,376 shares of Becton Dickinson and Co which is valued at $4,307,483. Becton Dickinson and Co makes up approx 0.04% of Blair William Coil’s portfolio.Ftb Advisors reduced its stake in BDX by selling 48 shares or 21.72% in the most recent quarter. The Hedge Fund company now holds 173 shares of BDX which is valued at $30,448.Sprucegrove Investment Management Ltd reduced its stake in BDX by selling 19,300 shares or 10.54% in the most recent quarter. The Hedge Fund company now holds 163,850 shares of BDX which is valued at $28,596,741. Becton Dickinson and Co makes up approx 1.12% of Sprucegrove Investment Management Ltd’s portfolio.Gwm Advisors boosted its stake in BDX in the latest quarter, The investment management firm added 4,024 additional shares and now holds a total of 23,241 shares of Becton Dickinson and Co which is valued at $4,053,230. Becton Dickinson and Co makes up approx 1.66% of Gwm Advisors’s portfolio.
Becton Dickinson and Co opened for trading at $172.54 and hit $173.3413 on the upside on Wednesday, eventually ending the session at $173.11, with a gain of 0.19% or 0.33 points. The heightened volatility saw the trading volume jump to 5,25,170 shares. Company has a market cap of $36,860 M.
On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Investors should note that on Jul 26, 2016, Becton Dickinson and Co announced a cash dividend of $0.6600. The company’s management has announced Sep 7, 2016 as the ex-dividend date and fixed the record date on Sep 9, 2016. The payable date has been fixed on Sep 30, 2016.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.